Abstract: Compositions comprising nanoparticles are described herein. At least a portion of the nanoparticles comprises a lipid and/or polymer which is water-insoluble, and an agent incorporated in the lipid and/or polymer. The nanoparticles are optionally associated with a surface of water-soluble particles which comprise a water-soluble compound. The polymer is optionally a polyanhydride. Further described herein are processes for preparing such compositions, comprising contacting a solution comprising the lipid and/or polymer dissolved in a non-aqueous solvent with an anti-solvent (in which the lipid and/or polymer and agent are insoluble) which is miscible with the non-aqueous solvent. Further described herein are uses of the compositions for nasal administration, and devices configured for nasal administration of the composition upon atomization.

Abstract: A porous particle, wherein the porous particle has a mass median aerodynamic diameter and a volume average particle diameter that satisfy expression: y?2x, where x denotes the mass median aerodynamic diameter and y denotes the volume average particle diameter, and the porous particle has a relative span factor (R.S.F) that satisfies expression: 0<(R.S.F)?1.5.

Abstract: The present invention provides a medical device containing a cake composition comprising aripiprazole as an active ingredient and capable of suppressing agglomeration of aripiprazole in a suspension obtained by resuspending a freeze-dried substance; and a cake composition comprising aripiprazole as an active ingredient. The present invention relates to a medical device containing, in a storage container whose inner wall is treated with silicone, a freeze-dried cake composition comprising separately prepared aripiprazole as an active ingredient, wherein there is a space between the inner wall and the cake composition; and a cake composition comprising aripiprazole as an active ingredient and having a strength of 5 to 100 N.

Abstract: The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof

Abstract: The disclosure relates to compounds and compositions for sustained release of ocular therapeutics.

Abstract: Silicone-in-water emulsions and methods for making same, are disclosed which are useful and effective as lubricants for use in intimate care applications, as a skin condition, as a surgical lubricant and/or as a carrier for an active topical pharmaceutical agent. In preferred examples, the emulsions of the present invention are flowable, have a viscosity of equal to or below about 15,000 centipoise (cP), and are stable upon storage for at least about 1 year.

Abstract: The invention relates to the use of, and methods of use employing, certain glycolipid compounds as defined in detail below and having preservative or antimicrobial properties, novel compounds of the glycolipid class, and related invention embodiments. The compounds have the formula I wherein m is 3 to 5, n is 2 to 5, o is 0 or 1 and p is 3 to 17, with the proviso that the sum m+n+o+p is not less than 14; and R is a carbohydrate moiety bound via one of its carbon atoms to the binding oxygen, and/or a physiologically, especially pharmaceutically or nutraceutically or cosmetically, acceptable salt thereof, or an ester thereof, as such or in the form of a composition, where the compound may be present in open chain form and/or in the form of a lactone (FIG. 1).

Abstract: A method of preparing a disinfecting composition comprising charged polyethylenimine (PEI), the method comprising adding a base to an aqueous solution comprising a linear PEI hydrochloride solution to provide a linear PEI salt solution with a pH between 9-11, adding a first organic acid to reduce the pH to less than 7, removing about 20% to 100% of the salt from the solution, and optionally adding water and/or a second organic acid to obtain the disinfecting composition with a pH of 2-7. The method can further comprise adding at least one metal salt to the disinfecting composition. The resulting disinfecting solution can be used to provide antimicrobial products with enhanced antimicrobial performance, reduced toxicity, and/or able to leave a persistent “kill-later” film.

Abstract: The present disclosure relates to a composition sustainable-releasing hydrogen sulfide for promoting wound healing and the method for preparing the same. The composition for promoting wound healing comprises a carrier and a plurality of hydrogen sulfide sustained releasing microspheres, wherein the hydrogen sulfide sustained releasing microspheres comprise a hydrophobic polymer, a surfactant and sodium hydrosulfide.

Abstract: Provided is a method for forming a good fibrous coating on a target surface even in a high-humidity environment when electrostatically spraying is performed directly on the target surface such as skin. A composition for forming a coating of fibers on a target object by electrostatic spraying, comprising the following components (a), (b), (c) and (d): (a) 1 mass % or more and 45 mass % or less of a polymer having a film-forming ability; (b) 45 mass % to 95 mass % of one or more volatile substances selected from the group consisting of an alcohol and a ketone; (c) a conductivity controlling agent to control the conductivity of the composition to 8 ?S/cm or more and 300 ?S/cm or less; and (d) 0.2 mass % or more and 25 mass % or less of water.

Abstract: A method for providing a steady state plasma concentration of about 20-400 ng/ml of isoflavonoid compounds comprising the steps of a first rectal administration of the compound in a lipophilic suppository base followed by further rectal administrations no earlier than 4, 8 or 16 hours after the previous rectal administration.

Abstract: A wet wipe that exhibits a novel combination of properties and methods for making such wet wipes are provided.

Abstract: Formulations and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed. The formulations generally comprise a TLR4 agonist and a metabolizable oil at a concentration of about 0.01%-1% v/v, wherein the hydrophobic:lipophilic balance (HLB) of the emulsion is greater than about 9.

Abstract: Described herein are compositions and methods for the increasing the quantity of lipids secreted from meibomian glands. Such compositions and methods are useful for the treatment of meibomian gland dysfunction and disorders resulting therefrom.

Abstract: The present invention relates to a technology for oral delivery of Poorly Bio-Available Therapeutic Agents and the formulations derived using this technology. Poorly Bio-Available Therapeutic Agents may belong to BCS class III/IV drugs or nutraceutical or any other agent which is required to be orally delivered having challenge of bio-availability in body. Therefore, invention further relates to a targeted delivery technology for enhanced bio-availability and controlled release without being degraded. The present invention further relates to the processes for the preparation of said compositions and formulations made thereof. The formulations of the present invention are useful to treat related conditions.

Abstract: Single phase cosmetic adhesive compositions that are flexible and resistant to water below a selected temperature, 43° C. for example. The adhesive compositions wear well, are smudge and flake resistant, as well as oil resistant, making them very suitable for long wear without adhesive failure. Adhesive compositions according to the invention comprise specific combinations of acrylates/VA copolymer and acrylates copolymer in a cosmetically acceptable base or delivery vehicle. Adhesive compositions according to the invention are hydrophilic and easily removed when scrubbed with water above a certain temperature, but not as easily removed with water below that temperature. The adhesive compositions are easy to manufacture, flexible and comfortable, and suitable for use on skin, lips, hair and nails, particularly to secure strips of false eyelashes and eyebrows, as well as individual lash and brow extensions.

Abstract: The instant disclosure relates to methods for treating chemically relaxed hair. The methods include applying a neutralizing composition to the chemically relaxed hair, the neutralizing composition comprising: at least 0.5 wt. % of at least one carboxylic acid, one or more C2-C6 monoalkanolamines, and water. The neutralizing composition is allowed to remain on the hair for a period of time. The hair is also treated with a neutralizing conditioner, which is a different than the neutralizing composition. The neutralizing conditioner includes: at least 0.5 wt. % of at least one carboxylic acid, one or more C2-C6 monoalkanolamines, one or more cationic surfactants, and water. The neutralizing conditioner is allowed to remain on the hair for a period of time. After treatment with a neutralizing composition and a neutralizing conditioner, the hair may be further treated with a shampoo, a conditioner, a conditioning shampoo, etc., dried, and/or styled.

Abstract: Provided is a polymer-based antimicrobial composition that is non-toxic, water soluble, and that mitigates the transmission of infectious diseases from surfaces. The composition comprises a cationic polymer, at least one adhesion promoter, optionally organic and/or inorganic particles that are photocatalytically active in visible light, and a carrier, in which the components of the composition are not covalently bound to one another. Also provided is an antimicrobial composition that comprises at least (i) a polyethylenimine-based polymer and a carrier or (ii) an organic and/or inorganic particle that is photocatalytically active in visible light, an adhesion promoter, and a carrier. The antimicrobial compositions can be applied to disinfect a surface and to form residual self-sanitizing films on the surface that are removable.

Abstract: A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.

Abstract: The invention relates to a nitric oxide-responsive acrylamide-based polymer, and more particularly, to an acrylamide-based polymer that is produced using an acrylamide-based monomer and a nitric oxide-sensitive crosslinking agent and allows prevention or treatment of a disease or illness caused by overexpression of nitric oxide.